Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Descrizione dettagliata
Study Design:
non-interventional uncontrolled observational study
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
-
Graz, Austria
- Boehringer Ingelheim Investigational Site 6
-
Salzburg, Austria
- Boehringer Ingelheim Investigational Site 5
-
Vienna, Austria
- Boehringer Ingelheim Investigational Site 1
-
Vienna, Austria
- Boehringer Ingelheim Investigational Site 2
-
Vienna, Austria
- Boehringer Ingelheim Investigational Site 3
-
Wels, Austria
- Boehringer Ingelheim Investigational Site 4
-
-
-
-
-
Bialystok, Polonia
- Boehringer Ingelheim Investigational Site 8
-
Bialystok, Polonia
- Boehringer Ingelheim Investigational Site 7
-
Bydgoszcz, Polonia
- Boehringer Ingelheim Investigational Site 9
-
Bydgoszcz, Polonia
- Boehringer Ingelheim Investigational Site 10
-
Chorzów, Polonia
- Boehringer Ingelheim Investigational Site 11
-
Chorzów, Polonia
- Boehringer Ingelheim Investigational Site 12
-
Gdañsk, Polonia
- Boehringer Ingelheim Investigational Site 13
-
Gdañsk, Polonia
- Boehringer Ingelheim Investigational Site 14
-
Gdañsk, Polonia
- Boehringer Ingelheim Investigational Site 15
-
Kraków, Polonia
- Boehringer Ingelheim Investigational Site 16
-
Kraków, Polonia
- Boehringer Ingelheim Investigational Site 17
-
Poznañ, Polonia
- Boehringer Ingelheim Investigational Site 18
-
Wroc£aw, Polonia
- Boehringer Ingelheim Investigational Site 19
-
Wroc£aw, Polonia
- Boehringer Ingelheim Investigational Site 20
-
-
-
-
-
Bacau, Romania
- Boehringer Ingelheim Investigational Site 50
-
Brasov, Romania
- Boehringer Ingelheim Investigational Site 51
-
Brasov, Romania
- Boehringer Ingelheim Investigational Site 52
-
Brasov, Romania
- Boehringer Ingelheim Investigational Site 53
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 21
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 22
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 23
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 24
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 25
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 26
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 27
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 28
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 29
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 30
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 31
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 32
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 33
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 34
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 35
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 36
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 37
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 38
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 39
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 40
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 41
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 42
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 43
-
Bucuresti, Romania
- Boehringer Ingelheim Investigational Site 44
-
Constanta, Romania
- Boehringer Ingelheim Investigational Site 46
-
Constanta, Romania
- Boehringer Ingelheim Investigational Site 47
-
Constanta, Romania
- Boehringer Ingelheim Investigational Site 48
-
Giurgiu, Romania
- Boehringer Ingelheim Investigational Site 45
-
Ploiesti, Romania
- Boehringer Ingelheim Investigational Site 49
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion criteria:
- HIV-1 infected male and female 18 years and above;
- anti-retroviral therapy (ART) naive and pre-treated patients switching from a nevirapine immediate release or other ART.
Exclusion criteria:
Consistent with the current VIRAMUNE prolonged release SPC.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
|---|
|
nevirapine extended release
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Patients Reporting Non-serious Adverse Events, Serious Adverse Events, and Non-serious and Serious Adverse Events Leading to Treatment Discontinuation
Lasso di tempo: up to 72 weeks
|
The primary endpoint is to evaluate the safety of a highly active antiretroviral therapy (HAART) that includes nevirapine extended release in routine clinical practice which is to assess the number of patients reporting non-serious adverse events (nSAEs), the number of patients with serious adverse events (SAE), the number of patients with non-serious adverse events leading to treatment discontinuation, and the number of patients with serious adverse events leading to discontinuation.
|
up to 72 weeks
|
|
Number of Patients Reporting Rash of Any Severity
Lasso di tempo: up to 72 weeks
|
Number of patients reporting rash of any severity as adverse event
|
up to 72 weeks
|
|
Number of Patients Reporting Hepatic Events
Lasso di tempo: up to 72 weeks
|
Number of patients reporting hepatic events either as adverse event (AE) or as laboratory abnormality of Grade 1 to Grade 4 in aspartate aminotransferase (AST), alanine transaminase (ALT), Gamma-Glutamyl-Transferase (Gamma-GT) and bilirubin.
|
up to 72 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Patients With Virologic Response at Week 24 (Viral Load <50 Copies/mL)
Lasso di tempo: 24 weeks
|
Virologic response is defined as confirmed Human Immunodeficiency Virus (HIV) viral load of < 50 copies/mL (at two consecutive measurements after baseline) up to week 24 and without subsequent rebound or change of anti-retroviral (ARV) therapy up to week 24.
A rebound is defined as two consecutive measurements of viral load (VL) ≥ 50 copies/mL, at least two weeks apart, after two consecutive measurements of VL< 50 copies/mL.
A change of ARV therapy is defined as a permanent discontinuation of nevirapine extended release, addition of new ARV drugs, or alteration in background therapy.
A change in the background therapy due to toxicity or intolerance is not considered as treatment failure.
If no follow-up viral load was available the virologic response is Missing.
|
24 weeks
|
|
Change in CD4+ Cell Count From Baseline to Week 24
Lasso di tempo: baseline and week 24
|
The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 24 weeks was calculated by subtracting the baseline value from the value after 24 weeks.
Therefore, a positive change represents an increase in CD4+ cell count.
|
baseline and week 24
|
|
Change in Morisky Medication Adherence Scale Score From Baseline to 24 Weeks
Lasso di tempo: baseline and week 24
|
The Morisky Medication Adherence scale (MMAS-8 scale) is a recognized indicator of medication adherence, consisting of 8 questions with a sum score ranging between 0 and 8 points.
The higher score indicates higher adherence to the prescribed therapy recommendation.
It has been agreed that the score of 8 could be categorized as having high adherence, score between 6 and 7 as medium adherence and scores of 5 and less as low adherence.
The change is presented as the score after 24 weeks minus the score at baseline.
Therefore, a positive change score reflects an improvement in the adherence.
|
baseline and week 24
|
|
Number of Patients Reporting Once Daily Nevirapine Intake More Convenient Than Twice Daily Formulation
Lasso di tempo: 24 weeks
|
The number of patients reporting that they find the once daily nevirapine intake more / very much more convenient than the twice daily formulation.
|
24 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Sindromi da deficit immunologico
- Malattie del sistema immunitario
- Infezioni da HIV
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 1100.1550
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .